Abstract | INTRODUCTION: AREAS COVERED: In this review, the authors discuss the role of ponatinib, an oral pan-inhibitor of BCR-ABL1, with potent activity in heavily pretreated patients, including T315I mutation. In the long-term follow-up of the PACE trial, 60% of patients with prior TKIs exposure achieved a major cytogenetic response with ponatinib and 40% a major molecular response; 5-year overall survival was 73%. Cardiovascular adverse events represent the major toxicity associated with ponatinib. Adopting a dose-reduction approach appeared to be safe: starting with 45 or 30 mg and decreasing to 15 mg once BCR-ABL1/ABL1≤1% is achieved. In patients who are not candidates for ponatinib therapy, asciminib or other novel TKIs like HQP1351, represent alternative options. EXPERT OPINION: In patients with CP-CML resistant or intolerant to second-generation TKIs, we favor using a third-generation TKI such as ponatinib. Although we initiate a donor search as soon as a patient fails a second-generation TKI, we still prefer treating patients with ponatinib and will only consider transplantation in the event of no response or disease progression.
|
Authors | Fadi G Haddad, Ghayas C Issa, Elias Jabbour, Musa Yilmaz |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 23
Issue 7
Pg. 751-758
(May 2022)
ISSN: 1744-7666 [Electronic] England |
PMID | 35412404
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Imidazoles
- Protein Kinase Inhibitors
- Pyridazines
- ponatinib
- Fusion Proteins, bcr-abl
|
Topics |
- Adult
- Antineoplastic Agents
(adverse effects)
- Drug Resistance, Neoplasm
- Fusion Proteins, bcr-abl
(genetics)
- Humans
- Imidazoles
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy)
- Leukemia, Myeloid, Chronic-Phase
(drug therapy, genetics)
- Protein Kinase Inhibitors
(adverse effects)
- Pyridazines
(adverse effects)
|